IL104974A - 4-demethoxy-4-substituted-anthracycline glycosides and their preparation - Google Patents

Description

104974/2 4-Demethoxy-4-substituted-anthracycline glycosides and their preparation FARMITALIA CARLO ERBA S.R.L.

C: 89106/9 glycosides, and process for their preparation.

DE 2 652 391, corresponding to GB 1 51 680, relates to daunosamyl anthracyclinones related to doxorubicin wherein the methyl in C-14 is substituted by as hydroxy, an acyloxy, an acylglycolloyloxy group or a tertiary amino group substituted, in its turn, by a Ci-C^ alkyl or together with the nitrogen atom to which said sub-stituents are attached, represents a 1-pyrrol i di nyl , a piperidino, a morholino or a 4-methyi-l-piperazinyl group.

Israel Patent Specification No. 92052, from which the present application was divided out, provides 4-substituted anthracyclinones of formula (I) wherein R represents a straight or branched alkenyl or alkynyl group of up to 16 carbon atoms, preferably of up to 4 carbon atoms, optionally substituted by (a) an aryl group which is unsubstituted or substituted by an inert group such as alkyl, alkoxy or nitro; (b) an alkoxy group; (c) a trialkylsilyl group; (d) an ester group or (e) a carbamoyl group.

The anthracyclinones of formula ( I ) are intermediates in the preparation of antitumor anthracycline glycosides.

The present invention provides anthracycline glycosides having the formula ( IX ) : wherein R is as defined above and Rt is a hydrogen atom or a hydroxy group; and their pharmaceutically acceptable salts.

Preferred acid addition salts are the hydrochloride salts.

The anthracyclinones of formula ( I ) and anthracycline glycosides of formula (IX) have a carbon-carbon bond at position C-4. In the definition of radical R, an aryl group is preferably phenyl. Alkyl and alkoxy groups are typically C^-Cj alkyl and C^-C^ alkoxy groups respectively. The ester group (d) is typically a (0Χ_4 alkox )carbonyl group. The alkenyl or alkynyl group may be substituted at one or more carbon(s) in the chain by a said group (a) to (e).

Preferred groups which R may represent are vinyl (ethenyl), allyl (propenyl, e.g. 2 ' -propenyl ) , trimethylsilyl-ethynyl, trimethylsilylvinyl, phenylethynyl or an alkoxy-carbonylvinyl group such as 21 -methoxycarbonylvinyl . The substituents are preferably attached to the 2 ' -carbon atom of the vinyl or ethynyl group and to the 3 ' -carbon atom of an allyl group.

Preferred compounds of formula ( I ) are selected from 4-demethoxy-4-ethenyl-daunomycinone, 4-demethoxy-4- ( 2 ' -methoxycarbonyl ) -ethenyl-daunomycinone, 4-demethoxy-4-trimeth 1sily1ethynyl-daunomycinone and 4-demethoxy-4- ( 2 ' -propenyl ) -daunomycinone . Preferred compounds of formula (IX) are 4-demethoxy-4-ethenyl- daunomycin and its hydrochloride.

The compounds of general formula ( I ) can be obtained from 4-O-sulfonyl anthracyclinones of formula (II): wherein R ' represents an alkyl group having from 1 to 10 carbon atoms optionally substituted by one or more halogen atoms or an aryl group optionally substituted by halogen, alkyl, alkoxy or nitro. Preferred groups which R' may represent are trifluoromethyl , 4-fluorophenyl and 4-toiyl. A carbon atom or chain is introduced at position C-4 under mild conditions to give compounds of formula (I) otherwise accessible only by total chemical synthesis. Moreover it . is noteworthy that none of the remaining functional croups is affected by the reaction and .the stereochemistry at C-7 and C-9 is completely preserved. 4-Substituted anthracyclinone of formula (I) can be obtained by a process which comprises reacting a 4-demethyl-4- (R 1 -sulfonyl ) -13 , 13-ethylenedioxy daunomycinone of formula (II) with: _ ------ (i) an unsaturated compound of formula (Ilia): K- " (Ilia) . . wherein R" is an alkenyl or alkynyl group of up to 15 carbon · atoms optionally substituted by a said group (a) to (e), or (ii) an organomecaliic compound of general formula (Illb) wherein M represents a metal atom, R is as defined above, n and m may each vary from 0 to 4 but n is not 0, and Y may be a halogen atom or a straight or branched alkyl group having 1 to 6 carbon atoms, in the presence of a catalytic amount of a compound of formula (IV) (hereunder referred to as catalyst): M'L L '. (IV) wherein M' represents a transition metal atom, L and L', which are the same or different, each represent an anion such as Ci~ or CH. COO" or a neutral molecule as a solvent molecule, a mono- or a di-phosphine , a phosphite or a diamine , and p and q may vary from 0 to 4 , to obtain a compound of formula (VI): (VI) wherein R is as defined above; and removing the 13-oxo protecting group by acid hydrolysis.

In the compound of formula (IV), preferred transition metal atoms which M' may represent are palladium or nickel. Preferred groups which L and/or L' may represent are chelating diphosphines such as 1 , 3-diphenylphosphinopropane , 1 , 1 '-bis-(diphenylphosphino ) ferrocene and 1 , 2-bis-[N-( 1-phenyethyl), N- { diphenylphosphino ) amino ] ethane . Typically m+n is at least 1, for example 1, 2, 3 or 4. The compound of formula (IV) is therefore a transition metal complex, preferably one between a transition metal atom such as palladium or nickel and a chelating agent such as above. The molar ratio of transition metal atom : chelating ligand is typically from 1:1 to 1:4.

The compounds of formula (Ilia) are unsaturated compounds capable of undergoing a Heck-type reaction.

Preferred unsaturated molecules which may be used are those known to undergo the Heck-type .reaction [R.F. Heck, Org.

React. 27 (1982) 345]; in particular trimethylsilyl acetylene, phenylacetylene , alkyl acrylates and vinyl trimethylsilane .

For compounds of formula (Illb), preferred metal atoms which M may represent are tin, zinc, cadmium and magnesium. Typically n is 1, 2, 3 or 4 whilst m may be 0, 1, 2, 3 or 4. The sum of m and n depends on the valency of M. When Y is a halogen atom, it may be chlorine, bromine or iodine. When Y is an alkyl group it may be methyl.

Compounds of formula (II) can be prepared from - 5 - 104974/2 naturally occurring daunomycinone (V) as described EP-A-0288268 and in European Patent No. 0337665 Compounds of formula ( I ) are synthesized in good yields and with high optical and chemical purity, directly from daunomycinone as summarized in Scheme 1.

The process for the preparation of formula ( I ) may be carried out as follows. Compounds of formula (II) are dissolved in an appropriate polar solvent and added, under an inert atmosphere, to a solution of catalyst, either preformed or generated in situ from suitable precursors, in the presence of an unsaturated compound (Ilia) able to undergo the Heck-type reaction or of an organometallic compound of formula (Illb), and optionally in the presence of a suitable base such as a trialkylamine. The temperature of the reaction is 104974/2 - 7 - from 0 to 150°C, preferably from 30 to 100°C, and the catalyst is used in a molar ratio to (II) of from 1:1 to 1:10000, preferably from 1:20 to 1:1000.

The compounds of general formula (VI) thus obtained are easily transformed into the final products (I) by acid hydrolysis of the protecting group at the C-13 carbonyl, for example at 0°C and for 45 minutes with trifluoroacetic acid. The crude compound of formula (I) thus obtained can be purified by chromatography on a silica gel column using as the eluent system chloroform: cetone (95:5 v/v).

The palladium-catalyzed arylation of unsaturated compounds (the Heck reaction) by using aryl halides has been known for a long time and many papers and patents dealing with its use in organic chemistry have been published [a) R.F. Heck, Org. React. 27 (1982) 345; b) A. Spencer, J.

Organomet. Chem. 258 (1983) 101; c) T. Jeffery, J. Chem.

Soc. Chem. Commun. (1984) 1287; d) L . Crombie, M . A.

Horsham, Tetrahedron Lett. 2_8 (1987) 4879]; much less work is reported in the scientific literature as far as aryl sulfonates are used as arylating compounds [Q.Y. Chen, Z.Y. Yang, Tetrahedron Lett. 27 (1986) 1171; J.W. Tilley, S.

Zawoiski, J. Org. Chem. 5_3 ( 1988 ) 386 ], Also the palladium or nickel-catalyzed coupling of aryl halides or sulfonates with organometallic compounds has been known for several years [ M . Kumada , Pure Appl . Chem. 5_2 (1980 ) 669 ; Q.Y. Chen, Y.3. He, Tetrahedron Lett. _28 ( 1987 ) 2387 ; A.M. .Echevarren, J.K. Sfcille, J. Am. Chem. Soc. 109 (1987) 5478].

However both classes of reactions have never been reported in the anthracycline chemistry, probably because of the presence of other interfering functional groups. The problems arising from the presence of said groups, namely aromatization of ring A, formation of 7-deoxy derivatives, hydrolysis of 4-sulfonyl derivatives and/or modifications of the quinone moiety can be suppressed under the conditions described in the parent application no. 92052.

The present invention also provides a process for the preparation of an anthracycline glycoside of formula (IX) or a pharmaceutically acceptable salt thereof, which process comprises: (i) reacting a 4-substituted anthracyc'linone of formula (I) with a halosugar of formula (X): Hal wherein Hal represents a halogen atom, the 3"-amino group is protected or unprotected and the 4"-hydroxy group is protected or unprotected, and, if present, removing the or each protecting group from the product thus-obtained such as to obtain an anthracycline glycoside of formula (IX) wherein Rx is a hydrogen atom; (ii) if desired, converting the said glycoside of formula (IX) thus obtained into a pharmaceutically acceptable salt thereof; (iii) if desired, brominating the said glycoside of formula (IX) or pharmaceutically acceptable salts thereof and hydrolysing the 14-bromo derivative thus obtained so as to form the corresponding glycoside of formula (IX) wherein RA is a hydroxy group and; (iv) if desired, converting the said glycoside of formula (IX) wherein R: is hydroxy into a pharmaceutically acceptable salt thereof.

Preferably the anthracyclinone of formula (I) is reacted with the halosugar of formula (X) in step (i) in an inert organic solvent under an inert atmosphere at a temperature of from 5 to 30°C and in the presence of silver trifluoromethanesulfonate ; if desired, the resulting anthracycline glycoside is isolated in step (ii) as its hydrochloride by treatment with methanolic hydrogen chloride; if desired, ste (iii) is effected by bromination and by hydrolysis of the 14-bromo derivative thus obtained and, if desired, the resulting anthracycline glycoside is isolated in step (iv) as its hydrochloride by treatment with methanolic hydrogen chloride.

An anthracycline glycoside of formula (IX) in which R1 is a hydrogen atom is therefore prepared by reacting an anthracyclinone of formula (I) with a halosugar of formula (X). In formula (X), Hal is typically a chlorine atom. If the 3"-amino group is protected, the protecting group may be a trifluoroacetyl group. If the 4"-hydroxy group is protected, the protecting group may also be a trifluoroacetyl group. The condensation of the anthracyclinone of formula (I) and halosugar of formula (X) generally takes place in the presence of silver trifluoromethanesulfonate (triflate).

The anthracyclinone may be dissolved in an inert organic solvent such as methylene dichloride, with the reaction taking place under an inert atmosphere such as argon at a temperature of from 5 to 30° C, typically at ambient temperature. Any protecting groups may be removed by mild alkaline hydrolysis, for example by treatment with O.IN aqueous sodium hydroxide. Preferably the anthracycline glycoside is isolated as its hydrochloride by treatment of the free base with methanolic hydrogen chloride.

The anthracycline glycoside of formula (IX) in which R is a hydrogen atom, or one of its salts, can be converted into the corresponding doxorubicin derivative in which R. is a hydroxy group by bromination at the 14-position and by hydrolysis of the 14-bromo derivative with aqueous sodium formate. The bromination and hydrolysis conditions are typically those described in US-A-4122076 or GB-A-1217133.

More specifically, the glycoside of formula (IX) in which Rr is a hydrogen atom, or one of its salts, can be reacted with bromine in chloroform to obtain a 14-bromo derivative from which, after hydrolysis at room temperature and for 48 hours under nitrogen with an aqueous solution of sodium formate, the compound of formula (IX) in which Rx is hydroxy is obtained as a free base and, by treatment with anhydrous methanolic HC1, is isolated as its hydrochloride.

The invention provides an anthracycline glycoside of formula (IX) and a pharmaceutically acceptable salt thereof.

The compounds of the invention are useful in methods of treatment of the human or animal body by therapy. They are useful as antitumor agents. A therapeutically effective amount is administered to a patient. An amount sufficient to inhibit the growth of the tumor may be administered. The tumor may be a Colon adenocarcinoma or Gross leukaemia tumor.

The following Examples illustrate the invention.

Example 1. 4-Demethoxy-4-ethenyl daunomvcinone Γ ( I ) .

R=CH=CH, .

To a solution of 1 g of 4-demethyl-4-trifluoro-methanesulfonyl-13,13-ethylenedioxy daunomvcinone [(II), R' = CF3] (1.78 mmol) in 50ml of dioxane, under an inert atmosphere, were successively added 1.55 ml of diisopropylethylamine, 0.3 ml of acetic acid, 55 mg of 1,1' bis-(diphenylphosphino)-ferrocene (0.097 mmol), 20 mg of palladium acetate (0.089 mmolj and 3.52 g of vinyltrimethyl silane (35.2 mmol). The reaction mixture was stirred at 60 °C overnight, then cooled to 0°C, acidified with 10% hydrochloric acid and extracted with methylene chloride. The organic phase was evaporated to dryness leaving the crude 4-demethoxy-4-(2 ' - trimethylsilyl )ethenyl-13, 13-ethylenedioxy daunomycinone [(VI), R = CH=CH-Si(CH3)3] . 104974/2 - 12 - ^H-NHR 300 MHZ (1n CDCl^ ): 6- 0.24 (9H, sj, 1.47 (3H, s), 1.95 (1H, dd, J=5.0;14.6 Hz), 2.44 (1H, d, J=14.6 Hz), 2.73 (1H, d, J=18.9), 3.18 (1H, dd, J=2.5;18.9), 3.29 (1H, s), 3.8 (1H, d, J=6.6 HZ), 4.08 (4H, s), 5.2 (1H, t, J=5.0 Hz), 6.32 (1Hf df J=18.9 HZ), 7.69 C1H, t, J=7.7 Hz)), 7.80 (1H, dd, J=1.0;7.7 Hz), 7.96 (1H, d, J=18.9 Hz), 8.24 (1H, dd, J=1.3;7.7 Hz), 13.24 (1H, s), 13.75 (1H, S).

U.V. (in EtOH) :,Α = 526, 492, 359, 256, 214 nm; max = 256 nm I.R. (KBr pellet ): - 3480, 1612^ 1585, 1575 cm^ [a]o°(c = °-1 1n dioxane) = + 179" M.S. m/z = 510 (M " ,base peak; TLC on Kieselgel plate F 254 (Merck) using chloroform/acetone (9: 1 by volume) Rf = 0.72 The crude [(VI), R = CH=CH-Si (CHj)5 ] was stirred at 0 'C in 6 mL of tnfluorcacetic acid and Ο.ά mL of water for 45 minutes. The reaction mixture was diluted with 150 mL of water and extracted with methylene chloride. The organic layer was washed with saturated sodium bicarbonate and water till neutrality, dried over sodium sulfate and evaocrated to dryness. The residue was° chromatographed . on silica gel (chloroform/acetone 95:5 by volume as eluant) obtaining 0.45 g [64 x from (II), R' = CF^ ], of 4-demethoxy-4-ethen 1 daunomycinone [(I), R = CH=CH?], (HPLC 97.8 X)..

HPLC analysis: Column: Herck RP 18/7 urn (250 x 4.2 mm), Mobile phase: A- 0.01 M sodium heptanesulfonate/0.02 M phosphoric acid 6 B- Hethanol 7 Acatonitri le 3 Gradient: from 205 B to 70S a 1n 25 min, 5 Flow rata:. 1.5 mL/min, Detector: UV at 254 nm.

-K-HHR 300 HHZ (in COCl^ ): 5= 2.15 (1H, dd, J=4.8;14.5 Hz), 2.35 (1H. dt, J=2.0:14.5 Hz), 2.42 (3H, s , 2.95 (1H, d, J=18.6 Hz). 3.20 (1H, dd, J=2.0;18.5 Hz) 3.-25.J 1H, dT J=5.7 Hz), 4.53 (1H, 10 s), 5.32 (1Hf raj, 5.51 (1H, dd, J=1.4; 11.0 Hz) , 5.64 (1H, dd, J=1.4;17.3 HZ), 7.74-7.92 (3H, m) , 8.37 (1H, dd, J=2.0;7.5 HZ), 13.28 (1H, s), 13.71 (1H,s).

U.V. (in 355, 255, 212 nn; max s 255 ran.

I.R. (KBr pellet ): - 3480, 1712, 1510, 1575 ca"^ . ! = [a]2°(c = 0.1 in diaxane) = ÷ 190* M.S. m/z = 394 (H 7.base peak) TLC an Kieselgel plate F 2S The crude [(VI), R = CH=CH-S1 (CH3 ^ ] was treated with trifluoroacatlc acid as described in example 1 obtaining, after chromatography on silica gel (chloroform/acetone 95:5 by volume as eluant) 0.41 g [5S.3 from (II), R' = CF3 ] of 4-demethoxy-4 -ethenyl daunomycinone [(I),R= CH=CH^] (HPLC 98.2 X).

Example 3. 4-Demethoxy-4- Γ ( 2 ' - (methoxycarbonyl ) ethenyl ] -daunonycincne CCD, R - CH=CH-CSOCHg.1 The reaction was carried out as -described in example 1 except that methyl acrylate (3.17 mL, 35.2 mrr.ol) was used as ·. reactant, obtaining the crude 4-demethoxy-4- [ 2 ' - ( methoxycarbonyl ) ethenyl]- 13,13-ethyTenedioxy daunomycinone! [ (VI) , R=CH=CH-COOCH3] .

H-NHR 300 HHZ U.V. (in EtCH): ,λ = £27, 492, 347, 264, 213 res; X max = 26* nm I. . (K8r pellet 3470, 1716, 1610, 157; cm~~. ta]4° (c = 0.1 in dicxane) = + 195* H.S. m/z = 4S6 (H "** , base peak) · TLC on Xieselgel plate F 254 (Herck) using- chloroform/acetone (9:1 by volume) Rf = 0.44.

The crude [ (VI), R = CH=CH-CCOCH - ] was treated with trif'iuoroacetic acid as described in example 1 obtaining, after chromatography on silica gel (chloroform/acetone 95:5 by volume eluant) 0.41 g 50.8 X from II , R = CF^ , o 4-demethoxy -4-(2'-methoxycarbanyl )ethanyl daunomyc none, t(I), R = CH=CH-CCOCH J ] , (HPLC 97.8 X).

^H-NHR 300 MHz (in CDClj ): δ= 2.16 (1H, dd, J=5.0;14,8 Hz), 2.36 (1H, dt, J=2.2;14.8 Hz), 2.43 (3H, S), 2.95 (1H, d, J=18.8 Hz), 3.21 (1Hf dd, J=2.2;18.8 Hz), 3.75 (1H, d, J=1.2 Hz), 3.87 (3H, s), 4.55 (1H, S), 5.34 (1H, bs), 6.26 (1H, d, J=15.8 Hz), 7.80-7.90 (2H, tn), 8.46 (1H, dd, J=2.9;6.2 Hz), 8.75 (1H, d, J=15.8 Hz), 13.24 (1H, s), 13.53 (1H, s).

U.V. (in EtOH): Λ = 493, 348, 265, 214 nm; = 265 nm.

I.R. (KBr pellet ): JJ - 3390, 1713, 1690, 1615, 1575 era"' . (c = 0.1 in dioxane) = + 188' M.S. m/z = 452 (H +" , base peak) TLC on ieselgel plate F 254 (Herck) using chloroform/acetone (9:1 by volume) Rf = 0.61 Example 4. 4-Demethoxy-4-[ ( 2 ' - ( methoxycarbonyl ) ethenyl]- daunomyc none [(I), R = CH=CH-COOCH^ ] The reaction was carried out as described in example 3, except that ditnethylfarmamide (50 mL) was used as solvent and 1,2-bis -[N-(l pheny lethy )-' N-(diphenylphosphino) amino] ethane (62 mg, 0.097 mmol) as ligand for palladium, obtaining, after chromatography on silica gel (chloroform/acstone 95:5 as eluant), 0.34 G [42% from (II), R'=CF3] of 4-demethoxy-4-{2 · -(methoxy carbonyl ) ethesyl ]. daunomycinone [(I), R=CH=CH-COOCH3] , (HPLC 98.2%).

Example S. 4-0emethoxy-4-tr1methylsi lylethynyl daunomycinone [(I), R = CSC-S1(CH,)¾] The reaction was carried out as described 1n example 1, except that trimethylsilyl acetylene (5.9 mL, 35.2 tnmol) was used as reactant, obtaining the crude 4-demethoxy-4-trimethylsi lylethynyl 13,13-ethylenedioxy daunomycinone [(VI), R' = C=C-Si(CH3)3].

^ H-NHR 300 HHz (in CDC15 ): δ= 0.35 (9H, s), 1.48 (3H, s), 1.99 (1H, dd, J=5.0;14.6 Hz), 2.47 (1H, d, J=14.6 Hz), 2.78 (1H, d, J=19.0), 3.15 (1H, bs), 3.23 (IH^dd, J=2.0;19.0 Hz), 3.82 (1H, bs), 4.08 (4H, s), 5.28 (1H, d, J=3.7 Hz), 7.72 (1H, t, J=7.7 Hz), 7.94 (1H,- dd, J=1.4;7.7 H∑), 8.34 (1H, dd, J=1.4;7.7 Hz), 13.22 (1H, s), 13.80 (1H, s).

U.V. (in EtOH): λ= 528,494,363,269,247,214 nm; λmax = 269 nm.

I.R. (KBr pellet ): V - 3540, 3470, 1615, 1565 «a"~ . [ ]2* (c = 0.1 in diaxane) = + 183" o M.S. m/z = 508 (M^", base peak) TLC on Kieselgel plate F 254 (Merck) using chloroform/acetcne (9:1 by volume) Rf = 0.65 The crude l(VI), R = C=C-Si(CH3 )3 ] was treated with trifluoroacetic acid as described in examole 1 obtaining, after chromatography on si Hca gel (chloroform/acetcne 95:5 by volume as eluant) 0.12 g [15 X fron (II), R' = CF^ ] of 4-demethoxy-4 -trimethylsilylethynyl daunomycinone [(I), R = C≡C-S1(CH5)5 ], (HPLC 96.4 S).

^H-HHR 300 HHz (in C0C15 ): δ= 0.30 (9H, s), 2.04 (1H, dd, J=4.8;14.6 HZ), 2.25 (1H, d, J=14.5 Hz), 2.34 (3H, s), 2.69 (1H, ' d, J=18.7 HZ), 2.91 (1H, dd, J=1.4;18.7 Hz), 4.06 (1H, d, J=5.6), 104974/3 4.71 OH, s), 5.11 (1H, t, J=4.2 Hz), 7.60 (1H, t,"j=7.8 Hz), 7.80 (1H, dd, J=1.3;7.7 Hz), 8.03 (1H, dd, J=1.3;7.7 Hz), 12.82 (1H, S), 13.29 (1Ht. S).

U.V. ( in EtOH): A = 493, 366, 269, 246, 222, 204 nm; / max = 269 nra.

I.R. (KBr pellet ): P- 3490, 1715, 1615, 1565 cnf^ H.S. m/z = 464 (H+, basa peak) TLC on Kieselgel plate F 254 (Merck) using chloroform/acetone <9:1 by volume) Rf = 0.44 Example 6. 4-Demethoxy-4- ( 2 ' propenyl )daunomycinone Γ ( I ) , R = CH2-CH=CH2] To a solution of lg of 4-demethyl-4-trifluoromethanesulfonyl-13,13- et ylenedioxy daunomycinone [(II), R' = CF3] (1.78 mmol) in 50 ml of dioxane, under an inert atmosphere, vers successively added 55 mg (0.097 mmol) of 1 , 1 'bis-(d1phenylphosphino)ferrocene, 20 mg (0.089 mmol) of palladium acetate and 1.1 mL (3.56 mmol) of allyl trimeth ltin. The reaction mixture was stirred at 70 'C ..overnight, then -ceded to 0 "C-and worked up as- described in example 1 obtaining crude 4-demethoxy-4- ( 2 ' ropenyl ) - 13,13-ethylenedioxy daunomycinone [(VI),R = CH2-CH=CH2] * H-HHR 300 HHZ (in COCI^ ): δ= 1.47 (3H, s) , 1.98 (1H, dd, J=5.0;14.7 Hz), 2.45 (1H, dt, J=2.0;14.7 Hz), 2.74 (1H, d, J=18.9 HZ), 3.14 (1H, S), 3.24 (1H, dd, J=2.2;18.9 Hz), 3.78 (1H, d, J=5.8 HZ), 4.06-4.12 (6H, m), 5.00-5.21 (2H, ra) , 5.22-5.30 (1H, m), 6.00-6.18 (1H, m), 7.60-7.75 (2H, m), 8.31 (1H, dd-, J=1.9;7.4 HZ), 13.36 (1H, S), 13.85 (1H, s).

- - U.V. ( i n EtOH): = 523, 489, 339, 287, 254, 207 nm; A max = 254 nm I.R. (KBr pellet )-.'J- 3470, 3335, 1615, 1575 cnf [a] 2° (c = 0.1 1n dloxane) = + 115* M.S. m/z = 452 (M , base peak ) TLC on ieselgel plate F 254 (Merck) using chloroform/acetone (9:1 by volume) Rf = 0.68 The crude [(VI), R = CH^ -CH-CH^ ] was treated with trifluoroacetic acid as described in example 1 obtaining, after chromatography on silica gel (chloroform/acetone 95:5 by volume as eluant) 0.51 g [70 X from (II), R' = CF5 ] of 4-demethoxy-4- (2'propenyl) daunomycmone [(I), R = CH^-CH=CHjg ], (HPLC 97.9 X).

^H-NHR 300 MHZ (in CDClj ): δ= 2.17 (1H, dd, J=4.8;14.5 Hz), 2.35 (1H, dt, J=2.0;14.5 Hz), 2.43 (3H,s), 2.94 (1H, d, J=18.7 Hz), 3.19 (1H, dd, J=2.2; 18.7 Hz), 3.77 (1H, bs), 4.08-4.12 (2H, m) , 4.55 (1H, bs), 5.02-5.13 (2H, m ) , 5.30-5.35 (1H, m ) , 6.04-6.19 (1H, m), 7.65 (1H, dd, J=1.8;7.7 Hz), 7.74 (1H, t, J=7.7 Hz), 8.33 (1H, dd, J=1.8;7.4 Hz), 13.28 (1H, s), 13.82 (1H, s ) U.V. (in EtOH): A = 489, 339, 286, 254, 208 nm; A max - 254 nm I.R. (KBr pellet ):J - 3410, 1710, 1618, 1575 cnf^ [al^3 (c = 0.1 i n dioxane) = + 152* M.S. m/z = 408 (M"** , base peak) TLC on Kieselgel plate F 254 (Merck) using chloroform/acetone (9:1 by volume) Rf = 0.78 104974/2 - 19 - Example 7: Preparation of 4-ethenyl-( 4-demethoxy )-daunomycin hydrochloride To a stirred solution of 4-ethenyl-( 4-deraethoxy )-daunomycinone (0,468g, 1.2 mmol) in CH2C12 (80 ml), at room temperature under argon, a solution of chlorodaunosammine (0.536g, 1.5 mmol) in CH2C12 (10 ml) and a solution of AgCF3S03 (0.398 g), 1.5 mmol) in Et20 (12 ml) were simultaneously added, over a ten minutes period. After 30 minutes, 0.144 ml of pyridine were added and the reaction mixture was filtered on dicalite. The solution was sequentially washed with HCl 1%, water, dried (Na2S04) and evaporated _in vacuo .

The residue was taken up with acetone (20 ml) , cooled to 0°C and treated with NaOH 0.075 M (100 ml). After an hour CH2C12 and water were added and the pH was adjusted to 4 with HCl 3%. The aqueous phase was separated, treated with NH4OH 1% to pH 8, and extracted with CH2C12 (3 x 100). The collected organic phases were dried over Na. S04 and evaporated in vacuo. The product was purified by Si02 column chromatography ( CH2 Cl2 /MeOH/CH3 COOH/H20=180/25/2/3 ) . The collected fractions were diluted with water and the pH adjusted to 8 with NH4 OH 1%. The organic phase was separated, dried and evaporated in vacuo to give 0.175 g of free base.

To a solution of the free base, in the minimum amount of CHC1. , 0.11 ml of HCl/MeOH 3N were added. The precipitate was filtered, washed with ether and dried obtaining 0.170 g of the title compound. (HPLC = 96.17%) 3 H-NMR 200 MHz { DMSO-d6 ) : S (ppra) - 1.16 (3H, d; J=6.6 Hz), 1.81 (2H, m), 2.12 (2H, m) , 2.27 (3H, s), 2.95 (2H, bs), 3.39 (1H, m), 3.58 (1H, bs ) , -4.21 (1H, q; J=6.6 Hz), 4.92 (1H, bs), 5.30 (1H, bs), 5.52 (3H, m) , 5.73 (1H, d; J=17.26 Hz), 7.85 (3H, m), 8.28 (1H, dd; J=7.05 Hz, J=1.87 Hz), 13.40 (2H bs) .

UV (EtOH): = 523.6, 489.6, 354.8, 258.4, 213.2 nm. max = 258.4 nm.

TLC on Kieselgel plate F 254 (MERCK) using CH2Cl2/MeOH/CH3COOH/H20 (8:2:0.7:0.3 by volume) Rf-0.83 Example 8: Preparation of 4-ethenyl-4-(demethoxy )-doxorubicin hydrochloride The title compound can be prepared from 4-ethenyl-4-(demethoxy)-daunomycin hydrochloride according to the procedure described in US-A-4122076. 0.2g of the 4-ethenyl-4-( demethoxy )-daunomycin hydrochloride is dissolved in a mixture of anhydrous methanol and dioxane. solution of lg of bromine in 10ml methylene chloride is added, as described in US-A-4122076, to afford the 14-bromo derivative. The 14-bromo derivative is hydrolysed at room temperature and for 48 hours under nitrogen with an aqueous solution of sodium formate. 4-Ethenyl-4-( demethoxy )-doxorubicin is thus obtained which, by treatment with anhydrous methanolic hydrogen chloride, is isolated as its hydrochloride .

Claims (3)

104974/4 - 21 - CLAIMS :

1. An anthracycline glycoside of formula (IX): wherein R represents a straight or branched alkenyl or alkynyl group of up to 16 carbon atoms optionally substituted by (a) an aryl group which is unsubstxtuted or substituted by an inert group, (b) an alkoxy group; (c) a trialkylsilyl group; (d) an ester group .or (e) carbamoyl group and Rx is a hydrogen atom or a hydroxy group; and pharmaceutically acceptable salts thereof.

2. . A process for the preparation of an anthracycline glycoside of formula (IX) according to claim .1 or a pharmaceutically acceptable salt thereof, which process comprises: (i) reacting a 4-substituted anthracyclinone of formula (I) as defined in claim 1 with a halosugar of formula (X) : , wherein Hal represents a halogen atom, the 3"-amino group is protected or unprotected and the 4"-hydroxy group is protected or unprotected, and, if present, removing the or each protecting group from the product thus-obtained such as to obtain an anthracycline glycoside of formula (IX) wherein R1 is a hydrogen atom; (ii) if desired, converting the said glycoside of formula (IX) thus obtained into a pharmaceutically acceptable salt thereof; (iii) if desired, ( brominating the said glycoside of formula (IX) or pharmaceutically acceptable salts thereof and hydrolysing the 14-bromo derivative thus obtained so as to form the corresponding glycoside of formula (IX) wherein R: is a hydroxy group and; (iv) if desired, converting the said glycoside of formula (IX) wherein R1 is hydroxy into a pharmaceutically acceptable salt thereof.

3. A process according to claim 2, wherein the anthracyclinone of formula (I) is reacted with the halosugar of formula (X) in step (i) in an inert organic solvent under an inert atmosphere at a temperature of from 5 to 30° C and in the presence of silver t ifluoromethanesulfonate ; if desired, the resulting anthracycline glycoside is isolated in step (ii) as its hydrochloride by treatment with methanolic hydrogen chloride; if desired, step (iii) is effected by bromination and by hydrolysis of the 14-bromo derivative thus obtained and, if desired, the resulting anthracycline glycoside is isolated in step (iv) as its hydrochloride by treatment with methanolic hydrogen chloride . for the Applicant